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Muhammad Imran Aslam1,2*, Maleene Patel1,2, Baljit Singh1,2, John Stuart Jameson2 and James Howard Pringle1,2Abstract
The development of Colorectal Cancer (CRC) follows a sequential progression from adenoma to the carcinoma.
Therefore, opportunities exist to interfere with the natural course of disease development and progression.
Dysregulation of microRNAs (miRNAs) in cancer cells indirectly results in higher levels of messenger RNA (mRNA)
specific to tumour promoter genes or tumour suppressor genes. This narrative review aims to provide a
comprehensive review of the literature about the manipulation of oncogenic or tumour suppressor miRNAs in
colorectal cancer cells for the purpose of development of anticancer therapies. A literature search identified studies
describing manipulation of miRNAs in colorectal cancer cells in vivo and in vitro. Studies were also included to
provide an update on the role of miRNAs in CRC development, progression and diagnosis. Strategy based on
restoration of silenced miRNAs or inhibition of over expressed miRNAs has opened a new area of research in cancer
therapy. In this review article different techniques for miRNA manipulation are reviewed and their utility for
colorectal cancer therapy has been discussed in detail. Restoration of normal equilibrium for cancer related miRNAs
can result in inhibition of tumour growth, apoptosis, blocking of invasion, angiogenesis and metastasis.
Furthermore, drug resistant cancer cells can be turned into drug sensitive cells on alteration of specific miRNAs in
cancer cells. MiRNA modulation in cancer cells holds great potential to replace current anticancer therapies.
However, further work is needed on tissue specific delivery systems and strategies to avoid side effects.
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Colorectal cancer (CRC) is the third most common neo-
plasm worldwide. According to the International Agency
for Research on Cancer, approximately 1.24 million new
cases of CRC were detected worldwide in 2008 [1]. The
incidence of CRC is on the rise in developing countries,
southern and eastern Europe [2-4]. Contrary to the
current trend in Europe, the incidence of CRC in the
USA has fallen in the last two decades [5]. The lifetime
risk for developing CRC [6] in men is 1 in 16 whereas in
women it is 1 in 20 (National Statistics, UK). The devel-
opment of CRC follows the sequential progression from
adenoma to carcinoma [7]. The initial genetic alteration
results in adenoma formation in which cells exhibit* Correspondence: mia7@leicester.ac.uk
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reproduction in any medium, provided the orautonomous growth. During the further course of car-
cinogenesis, intestinal epithelial cells acquire the charac-
teristics of invasion and potential for metastasis.
Therefore opportunities exist to interfere with the nat-
ural course of disease development and improve cancer
specific survival. Such therapeutic interferences can po-
tentially be chemo preventive for high risk individuals,
the early detection of colorectal neoplasia, chemothera-
pies to down stage the surgically resected or resectable
cancers, and therapies for palliation of symptoms in
advanced stage cancer. Discovery of microRNAs (miR-
NAs) and their utility in RNA interference has opened a
new era of cancer research and potential of new therap-
ies for cancer treatment. This narrative review aims to
provide a comprehensive review of the literature about
the manipulation of miRNAs in colorectal cancer cells
and tissue for the purpose of development of anticancer
therapies. Principles of miRNA manipulation and com-
mon methods of modulation in vitro and vivo are dis-
cussed in detail for the general understanding of readers.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of miRNAs in CRC development and the diagnostic util-
ity of circulating miRNAsMethods
A search was performed using Medline, PubMed and The
Cochrane Library databases from 2000 to 2011 to identify
articles reporting the role of miRNAs in colorectal cancer
development, diagnosis and therapy. The following MeSH
search headings were used: ‘microRNA’ and ‘colorectal
cancer’. The search was further extended by using the fol-
lowing text words and their combinations: ‘microRNA’,
‘blood’, ‘circulation’, ‘diagnosis’, ‘screening’, ‘therapy’, ‘manipu-
lation’, ‘modulation’, ‘stem cells’ and ‘miRNAs’. ‘The related
articles’ function in PubMed was used to broaden the
search. All the abstracts, studies and citations found were
reviewed. The most recent date of the search was 16 July
2011. Information about colorectal cancer related miR-
NAs was extracted on the following areas: cancer develop-
ment & progression; diagnostic utility; manipulation
in vitro and vivo; development of therapies. Detailed infor-
mation was extracted from studies that met the inclusion
criteria: Studies conducted on human and non-human
cells or tissues; blood-based miRNAs- in colorectal can-
cers and studies published in the English literature. Be-
cause of the lack of randomized controlled trials and the
heterogeneous nature of the available data, no attempt
was made to perform quantitative meta-analyses. In the
absence of standard criteria for the quality assessment of
laboratory-based, observational studies on miRNA and
heterogeneity of outcome measures included in this narra-
tive review, no quality assessment of included studies was
carried out. As the study is only a narrative review, no eth-
ical permission or approval was required.Results
The literature search identified 48 original scientific
studies and review articles in which some or all of the out-
comes of interest were reported. 18 additional articles and
web-based information sites were selected to provide a
general background to miRNA and colorectal neoplasia.
36 additional studies were included to supplement the in-
formation in colorectal cancer development, detection of
circulating miRNAs, and principles of miRNA therapy,
design and delivery. This article provides a comprehensive
review of the different approaches for restoration of
tumour suppressor miRNAs expression and methods of
knocking down the tumour promoter miRNAs in cancer
cells. Not all the methodologies of miRNA manipulation
have been applied to CRC cells and some have been
experimented only on other solid organ cancers. As de-
scription and elaboration of these methods might provide
an insight to future CRC therapies designed on miRNAmanipulations, the authors have included principle studies
focussing on mechanisms of such manipulation.
Discussion
MiRNA biogenesis and function
miRNAs are single-stranded, evolutionarily conserved,
small (17–25 ribonucleotides) noncoding [8] RNA mole-
cules. MiRNAs function as negative regulators of target
genes by directing specific messenger RNA cleavage or
translational inhibition through RNA induced silencing
complex termed as RISC [9,10]. So far around fourteen
hundred mature human miRNAs have been described in
the Sanger miRBase version 17 (An international registry
and database for miRNAs nomenclature, targets, func-
tions and their implications in different diseases). Fig-
ure 1 illustrates the biogenesis and mechanism of action
of miRNAs [11-18].
MiRNAs and colorectal cancer carcinogenesis
MiRNAs play an important role in colorectal tumour
biology including; oncogenesis; progression; invasion;
metastasis and angiogenesis [19-22]. Initiation and pro-
gression of colorectal neoplasia results from sequential
accumulation of genetic alterations in oncogenic and
tumour suppressor genes in colonic epithelium [23].
MiRNAs interfere with these genetic mutations and are
involved in different stages of cancer of colorectal neopla-
sia. Slaby and colleagues summarized the role of different
miRNAs in the development of colorectal cancer and
emphasized the importance of Adenomatous Polyposis
Coli (APC), Tumour Protein 53 (TP53) gene mutations
and the WNT signalling Pathway [24]. The initiation of co-
lonic neoplasia is strongly linked to inactivation of the
APC gene and activation of the WNT Signalling Pathway.
APC inactivation has been found in more than 60% of co-
lonic tumours and such inactivation is associated with up
regulation of miR-135a/b in colonic epithelial cells
[23,25,26]. Accumulation of any further somatic mutations
leads to further dysregulation of miRNAs and activation of
additional downstream pathways. For example let-7, miR-
18a* & miR-143 are strongly linked to KRAS knockdown
and activation of the EGFR-MAPK pathway [27-29]
whereas miR-21 and miR-126 are associated with augmen-
tation or inactivation of the phosphatidylinositol-3-kinase
(PI-3-K) pathway repectively [30,31]. Activation of these
downstream pathways results in autonomous tumour cell
growth, increased cell survival, and initiation of angiogen-
esis. Loss of P53 is a critical step in transformation of ad-
enoma to adenocarcinoma as nearly 50–70% of colonic
adenocarcinomas are found to be P53 mutant [23]. miR-
34a has been identified as a direct downstream target of
P53 and the replacement of miR-34a has achieved p53
induced effects of apoptosis and cell cycle arrest [32]. A
commonly up regulated miR-17-92 cluster (miR-17, miR-
Figure 1 Figure illustrates the biogenesis of miRNAs in the cellular nucleous, its transport to the cytoplasm, and processing by Drosha
and Dicer Enzymes. The figure also illustrates the RISC incorporation of miRNAs for functional activity in different pathways of translational
inhibition or activation. In brief, miRNAs are mostly transcribed from intragenic or intergenic regions by RNA polymerase II into primary transcripts
(pri-miRNAs) of variable length (1 kb- 3 kb). In the nucleus Pri-miRNA transcript is further processed by the nuclear ribo-nuclease enzyme ‘Drosha’
thereby resulting in a hairpin intermediate of about 70–100 nucleotides, called pre-miRNA. The pre-miRNA is then transported out of the nucleus
by a transporting protein exportin-5. In the cytoplasm, the pre-miRNA is once again processed by another ribonuclease enzyme ‘Dicer’ into a
mature double-stranded miRNA. Two strands of double stranded miRNA (miRNA/miRNA* complex) are separated by Dicer processing. After
strand separation, mature miRNA strand (miRNA- also called the guide strand) is incorporated into the RNA-induced silencing complex (RISC),
whereas the passenger strand, denoted with a star (miRNA*) is commonly degraded. This miRNA/RISC complex is responsible for miRNA function.
If on miRNA cloning, or miRNA array, the passenger strand is found at low frequency (less than 15% of the guide strand) it is named miR*.
However, if both passenger and guide strand are equal in distribution, then these two strands are named the 3p and 5p version of miRNA
depending on their location to either 5' or 3' of the miRNA molecule. In this case both strands can potentially incorporate in position into the
RISC complex and have a biological role [9-14]. The specificity of miRNA targeting is defined by Watson–Crick complementarities between
positions 2 to 8 from the 5 primed end of the miRNA sequence with the 3′ untranslated region (UTR) of their target mRNAs. When miRNA and its
target mRNA sequence show perfect complementarities, the RISC induces mRNA degradation. Should an imperfect miRNA–mRNA target pairing
occur, translation into a protein is blocked [9,10]. Regardless of which of these two events occur, the net result is a decrease in the amount of
protein encoded by the mRNA targets. Each miRNA has the potential to target a large number of genes (on average about 500 for each miRNA
family). Conversely, an estimated 60% of the mRNAs have one or more evolutionarily conserved sequence that is predicted to interact with
miRNAs [9,10,15]. miRNAs have been shown to bind to the open reading frame or to the 5′ UTR of the target genes and, in some cases, they
have been shown to activate rather than to inhibit gene expression [16]. Researchers have also reported that miRNAs can bind to
ribonucleoproteins in a seed sequence and a RISC-independent manner and then interfere with their RNA binding functions (decoy activity) [17].
MiRNAs can also regulate gene expression at the transcriptional level by binding directly to the DNA [18].
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the progression of adenoma to adenocarcinoma by up
regulation of c-myc [33]. Figure 2 summarises the inter-
action of different miRNAs in signalling pathways forcolorectal cancer development and progression.In the
KEGG pathway, it shows the interaction of different miR-
NAs in the formation of adenoma and its progression to
adenocarcinoma.
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Figure 2 Carcinogenesis of colorectal cancer cells and role of different miRNAs in cancer pathways. In the carcinogenesis of CRC, higher
levels of miR-135a & miR-135b are associated with low levels of Adenomatous Polyposis Coli (APC) , which in turn leads to activation of the Wnt
signalling pathway. Activation of the Wnt signalling pathway is a major tumour initiating event in the colonic epithelium. The low level of APC
associated β-catenin degradation complex results in the formation of free cytoplasmic β-catenin that enters the nucleus and activates Wnt-
regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators (Survivin,
c-Myc and Cyclin D1). As a consequence, there is a lack of apoptosis and increase proliferation of abnormal cells that results in autonomous
growth and formation of adenoma. During the course of carcinogenesis, cells in adenoma accumulate few other genetic alterations leading to
activation of other signalling pathways e.g. mitogen activated protein kinase (MAPK), Phosphatidylinositol 3-kinases (PI3K) and transforming
growth factor-beta (TGFβ) pathways. The let-7 miRNA family, miR-18a* and miR-143 are adept at inhibiting the KRAS translation hence switching
“off” the MAPK phosphorylation and inactivation of downstream transcription factors c-Myc, c-Fos and c-Jun. Furthermore, a targeted degradation
of PTEN and p85β by miR-21 and miR-126 respectively , blocks the PI3K-Akt pathway. These changes drive the early adenoma to a large
advanced adenoma. The loss of p53 function is associated with low expression levels of miR-34a family, indicating the role of this miRNA family
in the transformation of adenoma to the carcinoma.
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pathway has recently gained acceptance and is for the most
part, APC and TP53 mutation independent. It involves dis-
tinct molecular features of somatic BRAF mutation con-
cordance with high CpG islands methylation phenotype
(CIMP-H) and microsatellite instability (MSI+) associated
with mutt homologue 1 (MLH1) methylation [34,35]. In-
volvement of the miRNAs in the latter pathway is slowly
emerging and would require further functional studies to
find the link of miRNAs associated with this pathway.
Functional and mechanistic studies of miRNAs have
shown that the replacement or knockdown of distinct miR-
NAs in vitro resulted in distinct cytogenetic abnormalities
leading to either tumour cell proliferation or apoptosis[20]. That’s why it is believed that dysregulation of miRNA
genes that target mRNAs for tumour suppressor or onco-
genes contributes to tumour formation by inducing cell
proliferation, invasion, angiogenesis and decreased cell
death [19]. This has further lead to belief that over
expressed miRNAs in tumour cells function by inhibiting
different tumour suppressor genes whereas miRNAs that
are often found silenced in tumour cells downregulate the
expression of oncogenes in normal tissue (Figures 3 & 4).
Amplification, translocation, pleomorphism or mutation in
miRNA transcribing genes results in over production of
miRNAs. In contrast, mutation, deletion, promoter methy-
lation or any abnormalities in the miRNA biogenesis results
in silencing of miRNAs in tumour cells [19]. Table 1
Figure 3 Figure illustrates the mechanism of biogenesis and function of OncomiRNAs. Amplification, translocation, mutation or
pleomorphism in miRNA transcribing genes results in over production of pri-miRNA and pre-miRNAs in the nucleous. Further processing by the
DICER results in higher levels of mature miRNAs in the cytoplasm. These overexpressed miRNAs target tumour suppressor mRNAs in the
cytoplasm and lead to the downregulation of mRNAs.
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cancer tissue in comparison to adjacent healthy colonic
mucosa [36-49].
Diagnostic utility of circulating miRNAs
Recent studies have shown that tumour-derived miRNAs
are present in human body fluids in a remarkably stable
form and are protected from endogenous ribonuclease ac-
tivity. In three different studies researchers have evaluated
the suitability of circulating miRNAs as a diagnostic bio-
marker for CRC [50]. Preliminary studies suggest that CRC
derived miRNAs are present in the circulation at detectable
levels [51-54] and can accurately distinguish healthy con-
trols from patients with CRC (Table 2). Significantly high
sensitivity and specificity for detection of CRC holds prom-
ise for the use of circulating miRNAs as a diagnostic bio-
marker for CRC. Furthermore, the ability of a miRNA
based blood assay to detect colonic adenoma can lead to
its use in early detection and bowel cancer screening.Although a small number of studies have identified circu-
lating miRNAs in CRC patients, the clinical utility of this is
still questionable. This is due to an overlapping miRNA ex-
pression with other solid organ cancers and benign colonic
diseases, and variability of individual miRNA expression
with tumour site & stage. It is possible that the utility
of tumour tissue specific expression-signature/profile
may prove more informative and accurate in future
clinical studies. Furthermore, the discovery of exo-
some mediated transport of miRNAs into the circula-
tion, has shifted the focus of miRNA studies towards
the isolation of tissue specific circulating exosomes
and their contained miRNAs [55].
Principles of miRNA therapy
The fact that miRNAs regulate multiple genes in a mo-
lecular pathway, makes them excellent candidates for gene
therapy. One of the most appealing properties of miRNAs
as therapeutic agents is their ability to target multiple
Figure 4 Figure shows the proposed mechanism of biogenesis and function of tumour suppressor miRNAs. Promotor hypermethylation/
deactylation, homogygous/hetrotogygous deletion, mutation or pleomorphism in miRNA transcription gene results in under production or
complete loss of pri-miRNAs. Defects in miRNA processing machinery i.e. ineffective processing by Drosha/Dicer or defective pairing with RISC
can result into inefficient levels of mature miRNAs in the cytoplasm. Low levels of tumour suppressor miRNAs result in over expression of
oncogenic mRNAs (Ras, Bcl2, Mcl1).
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them extremely efficient in regulating distinct biological
cell processes relevant to normal and malignant cell
homeostasis. The rationale for using miRNAs as antican-
cer drugs is based on two major principles:
1. MiRNA expression is deregulated in cancer
compared with normal tissues
2. Cancer phenotype can be changed by targeting
miRNA expression
MiRNA based gene therapy is based on these two prin-
ciples where manipulation of miRNA expression levels in
cancer tissue results in inhibition of tumour growth, apop-
tosis, blocking of invasion, angiogenesis and metastasis.
Restoration of the normal equilibrium for cancer related
miRNA expression levels can result in growth retardation
and reduced cell viability both in vivo and in vitroexperiments. The major obstacle in gene therapy is the
safe delivery to specific target tissue without side effects.
Rapid degradation by body nucleases and poor cellular up-
take owing to the unfavourable chemical structure of syn-
thetic miRNAs have forced researchers to try chemical
modifications of synthetic oligonucleotides as well as a
more effective means of delivery. To overcome these de-
livery hurdles, viral and non-viral strategies have been
developed. Restoration of tumour-suppressor miRNAs in
cancer cells is usually achieved in vitro by using
adenovirus-associated vectors (AAV). These vectors do
not integrate into the genome and are eliminated effi-
ciently with minimal toxicity. There are multiple AAV ser-
otypes available, allowing for the efficient targeting of
specific tissues including colorectal tissue. The ability of
miRNAs to regulate several genes, does create potential
problem in terms of side effects. This is a major concern
in miRNA therapeutics as such interactions may lead to
Table 1 Summary of dysregulated miRNAs in CRC compared to adjacent normal mucosa
Studies Downredulated miRNAs in CRC tissue Upregulated miRNAs in CRC tissue
Michael, et al, 2003[36] let-7, miR-16, miR-24, miR-26a, miR-102, miR-
143, miR-145, miR-200b
Volinia, et al, 2006 [37] let-7a-1, miR-9-3, miR-23b, miR-138, miR-218 miR-16, miR-17-5p, miR-20a, miR-21, miR-29b ,miR-141, miR-195, miR-
199a
Xi , et al, 2006 [32] let-7b, let-7 g , miR-26a , miR-30a-3p, miR-
132, miR-181a, miR-181b, miR-296, miR-320,
miR-372
miR-10a, miR-15b ,miR-23a, miR-25, miR-27a, miR-27b, miR-30c, miR-
107, miR-125a, miR-191, miR-200c, miR-339
Bandrés, et al, 2006 [38] miR-133b, miR-145 miR-31, miR-96, miR-135b, miR-183
Akao, et al, 2006 [27,39] miR-143, miR-145, let7
Nakajima, et al,2006 [40] let-7 g, miR-181b, miR-200c
Lanza, et al, 2007 [41] miR-17-5p, miR-20, miR-25, miR-92, miR-93-1, miR-106a
Rossi, et al, 2007 [42] miR-200b, miR-210 , miR-224 miR-19a, miR-20, miR-21, miR-23a, miR-25, miR-27a, miR-27b, miR-29a,
miR-30e, miR-124b, miR-132, miR-133a, miR-135b, miR-141, miR-147,
miR-151, miR-152, miR-182, miR-185
Monz, et al, 2008 [43] miR-145 miR-17-5p ,miR-21, miR-30c, miR-106a, miR-107, miR-191, miR-221
Schepeler, et al, 2008 [44] miR-101, miR-145, miR-455, miR-484 miR-20a, miR-92, miR-510, miR-513
Schetter, et al, 2008 [45] miR-20a, miR-21, miR-106a, miR-181b, miR-203
Arndt, et al, 2009 [46] miR-1, miR-10b, miR-30a-3p, miR-30a-5p,
miR-30c, miR-125a, miR-133a, miR-139,
miR-143, miR-145, miR-195, miR-378*,
miR-422a, miR-422b, miR-497
miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-25, miR-
29a, miR-29b, miR-31, miR-34a, miR-93, miR-95, miR-96, miR-106a, miR-
106b, miR-130b, miR-181b, miR-182, miR-183, miR-203, miR-224
Slattery, et al, 2011 [47] miR-143, miR-145, miR-192, miR-215 miR-21, miR-21*, miR-183, miR-92a, miR-17, miR-18a, miR-19a, miR-34a
*Over expressed or under expressed miRNAs identified by two or more than two studies are underlined whereas the miRNAs with conflicting expression levels in
different studies are identified in Bold.
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been approached by using nano-particles and tissue spe-
cific non viral vectors. However, the concentration
dependent knockdown of non specific targets still remains
an unresolved issue. This article provides a comprehensive
review of the different approaches for restoration of
tumour suppressor miRNAs expression and methods of
knocking down the tumour promoter miRNAs in cancer
cells. Not all the methodologies mentioned in this articleTable 2 Summary of sensitivity and specificity of different dia
Tissue type Studies Participants
Whole Plasma Pu, et al, 2010 [51] CRC (n = 103)
Controls (n = 37)
Plasma Cheng , et al, 2011 [52] CRC I-IV (n = 102)
Controls (n = 48)
RNA Ng, et al, 2009 [53] CRC (n = 90)
Controls (n = 40)
Huang, et al, 2010 [54] CRC (n = 100)
Adenomas* (n =
Controls (n = 59)
*Adenoma cases.have been applied to CRC cells, but all have been investi-
gated as a therapy for other cancers. The description and
elaboration of these methods may provide an insight to
miRNA therapies in CRC.
Blocking oncogenic MiRNAs using antisense
oligonucleotides
The demonstration that oncogenic miRNAs are upregu-
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sion. Antisense oligonucleotides work as competitive inhi-
bitors of miRNAs, presumably by annealing to the mature
miRNA guide strand and inducing degradation of mature
miRNAs (Figure 5). The stability, and specificity for target
miRNAs and the binding affinity of antisense oligonucleo-
tides has been optimised by modifications to the chemical
structure of the oligonucleotides [57]. In particular the
introduction of 2′-O-methyl or 2′-O-methoxyethyl groups
to oligonucleotides enhances resistance to nuclease enzyme
and improves the binding affinities to RNA [58]. The silen-
cing of endogenous miRNAs by this novel method has
shown to be long lasting, specific and efficient both in vitro
[59,60] and in vivo. In CRC cells lines, antimiR based
blockage of oncogenic miRNAs (miR-20a, miR-21, miR-31,
miR-95, miR-672) has not only shown to reduce cell prolif-
eration, transformation and migration, but it has resultedFigure 5 Figure demonstrates the mechanism of Knockdown of onco
reversed by a) transcriptional inhibition of genes transcribing miRNAs of on
antisense oligonucleotides c) mRNA mask constructs causing competitive i
induction of SNPs in RISC complex.in enhanced sensitivity to chemotherapy agents [61-66].
This strategy of sensitizing the chemotherapy resistant
tumour cells with alteration of miRNA expression in
tumour cells may result in improved response to traditional
chemotherapy agents. Table 3 summarizes the studies ma-
nipulating the oncogenic miRNAs in colorectal cell lines.
Blocking oncogenic MiRNAs using locked nucleic acid
(LNA) Constructs
LNA construct based anti-miR therapeutic strategy has
been extensively explored by researchers studying the
miRNA based antiviral therapy for chronic hepatitis-C
[66]. LNA nucleosides are a class of nucleic acid analo-
gues in which the ribose ring is 'locked' by a methylene
bridge connecting the 2′-O atom and the 4′-C atom. By
locking the molecule with the methylene bridge, LNA
oligonucleotides display unprecedented hybridizationmiRs. The downregulation of tumour suppressor mRNAs can be
cogenic potential b) competitive inhibition of mature miRNAs with
nhibition to miR/RISC d) sponge constructs mimicking target mRNAs e)
Table 3 Summary of in vitro effects of antisense oligonucleotides and locked nucleic acid based oncogenic miRNA
manipulation in colorectal cell lines
miRNA Cell line Target Method Reported effects of miRNA manipulation References
antisense oligonucleotides
miR-20a SW480 BNIP2 anti–miR-20a Increased sensitivity to fluorouracil, oxaliplatin,
and teniposide
Chai, et al, 2011[61]
SW620
miR-21 RKO Pdcd4 anti-miR-21 Reduced intravasation and distal metastasis Asangani, et al, 2008[62]
miR-31 HCT-116 anti-miR-31 Reduced migration and increased invasion Wang , et al, 2010[63]
Reduced proliferation only with combined 5-FU
miR-95 HCT-116 LoVo SNX1 anti–miR-95 Reduces cell proliferation Huang , et al, 2011[64]
EGFR
miR-675 CaCO2 HCT116 RB anti-miR-675 Reduced cell growth and colony transformation Tsang , et al, 2010 [65]
HT-29 SW480
Locked nucleic acid (LNA)
miR-21 SW480 hMSH2 hMSH6 LNA anti-miR-21 Increased sensitivity to 5-FU Valeri, et al, 2010 [67]
HCT-116
RKO
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and complementary single-stranded or double-stranded
DNA [68]. In addition, they display excellent mismatch
discrimination and high aqueous solubility. So-called
'LNA anti-miR' constructs has been used successfully by
Valeri and colleagues [67] to knock down miR-21 in
colon adenocarcinoma cell lines.
Blocking oncogenic MiRNAs using MiRNA sponge
constructs
miRNA sponges based techniques to manipulate onco-
genic miRNAs is still in its infancy and has not been stud-
ied in detail in CRC cells. miRNA sponges are transcripts
that contain multiple tandem-binding sites to a miRNA of
interest and are transcribed from mammalian expression
vectors. Ebert and colleagues recently reported the use of
miRNA sponges in mammalian cells [69]. The authors
reasoned that miRNA target sequences expressed at high
levels could compete with bona fide targets in a cell for
miRNA binding (Figure 5). To increase the affinity of
these decoy transcripts, the researchers introduced not
only multiple miRNA binding sites, but also a bulge at the
position normally cleaved by argonaute 2, therefore facili-
tating the stable association of miRNA sponges with ribo-
nucleoprotein complexes loaded with the corresponding
miRNA. Using these constructs, repression of miRNA tar-
gets was observed and proved effective in vitro silencing
of miRNAs [69]. Theses effects were comparable with
those obtained with 2′-O-methyl-modified oligonucleo-
tides or LNA antisense oligonucleotides. Furthermore,
sponges that contained only the heptameric seed were
shown to effectively repress an entire miRNA family that
shares by definition the same seed sequence [69].Blocking oncogenic MiRNAs using MiRNA masking
antisense oligonucleotides
MiRNA masking effect strategy is designed to target sin-
gle signalling cancer pathways. miR-mask (miRNA-mask-
ing antisense oligonucleotides) technology has been
developed by Xiao and colleagues [70]. In contrast to
miRNA sponges, miR-masks consist of single-stranded
2′-O-methyl-modified antisense oligonucleotides that
are fully complementary to predicted miRNA binding
sites in the 3′ UTR of the target mRNA [70]. In this way,
the miR-mask covers up the miRNA-binding site to hide
its target mRNA (Figure 5), thereby its effects are gene
specific. This technology has been applied successfully in
a zebrafish model to prevent the repressive actions of
miR-430 in the transforming growth factor-β signalling
pathway [71]. Although unwanted effects or off-target
effects can be dramatically reduced with this approach,
this may be a disadvantage for cancer therapy in which
the targeting of multiple pathways may be desirable.
Blocking oncogenic MiRNAs using inhibitors of oncogenic
pathways
Several drugs may have the ability to modulate the expres-
sion of miRNAs by targeting signalling pathways that ul-
timately converge on the activation of transcription
factors which in turn regulate miRNA encoding genes.
Furthermore, it is possible to modulate the machinery that
contributes to miRNA maturation and degradation pro-
cesses. The identification of these compounds, however, is
not straightforward and requires efficient screening of
chemical libraries. Recently, Gumireddy and colleagues
identified a method to screen for small-molecule inhibi-
tors of miRNAs [72]. As a proof of concept for this
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and up-regulated miRNA, miR-21. Complementary
sequences to miR-21 were cloned into a luciferase re-
porter gene, which was then used as a sensor to detect the
presence of specific mature miRNA molecules. The con-
struct was transfected into HeLa cells, which express high
miR-21 levels, resulting in low luciferase activity. Subse-
quently, a primary screen of more than several small-
molecule compounds was done and an initial hit com-
pound, diazobenzene 1, produced a 250% increase in the
intensity of the luciferase signal relative to the untreated
cells [72]. Additional characterization showed that this
compound affects the transcription of miR-21. This strat-
egy could be applied to the screening of small molecules
as inhibitors for other distinct oncogenic miRNAs. These
could be used with conventional cancer therapeutics to
develop novel combined approaches for cancer treatment.
Restoration of tumour-suppressor miRNAs
The loss or downregulation of a tumour-suppressor
miRNA could be overcome by introducing synthetic oli-
gonucleotides i.e. mature miRNA mimics, miRNA pre-
cursors or pre-miRNA mimics into the CRC cells
(Figure 6). Introduction of synthetic miRNAs with
tumour-suppressor function in cancer cells have been
shown to induce cell death and block cellular prolifera-
tion, transformation, invasion and migration in several
studies as summarized in Table 4. The altered expression
of tumour suppressor miRNAs have been studied in the
context of cancer-associated transcription factors. P53
mutations have been found in 40–50% of CRCs. The
p53 protein is a transcription factor that regulates mul-
tiple cellular processes in CRC development, either by
regulating mRNA directly or by regulating miRNA indir-
ectly. The absence of p53 mutations in adenomas sug-
gests that loss of p53 is a critical step in progression of
adenoma to carcinoma [73,74]. In addition, the miR-34
family has been strongly linked to p53 and loss of p53
has been linked to reduced levels of miR-34 in cancer
cells. miR-34a restoration studies [75,76] have clearly
demonstrated reduced cell survival, invasion and migra-
tion in CRC cell lines. In addition to a link with the p53
pathway, miR-34a encoding genes on their own have
been identified as targets for the mutational or epigen-
etic inactivation in different cancers. Interestingly, miR-
34a resides on the chromosomal locus 1p36, which has
been proposed to harbor a tumor suppressor gene be-
cause it displays homozygous deletions in neuroblastoma
and in other tumor types [77]. An unbiased screen for
genes with tumor suppressive function on 1p36 also
revealed miR-34a as a candidate tumor suppressor gene
[78]. Therefore miR-34 targeted gene therapies hold a
prime importance in the designing therapies for chemo-
prevention and to halt the tumour progression. miR-143is another tumour suppressor miRNA, significantly
found downregulated in CRC tissues (Table 1). The most
significant study in this respect is restoration of miR-143
with miR-143 precursor resulting in reduced prolifera-
tion in SW480 colorectal cell lines and tumour suppres-
sion on xenografted tumors of DLD-1 human CRC cells
[79,80]. Restoration of tumour suppressor miRNA by
intravenous injection in mouse with liver cancer resulted
in the suppression of tumorigenicity by reduced tumour
growth and enhanced tumour apoptosis without signs of
toxicity. This illustrates that tumour suppressor miRNA
restoration strategy based gene therapy, if delivered
efficiently to specific tissues may prove vital in future
cancer treatments.
Modulation of miRNA processing
Alterations in miRNA processing machinery have also
been implicated in cancer development and modulation
of this machinery in part or in general can potentially
lead to the discovery of new anticancer therapies.
Researchers have investigated the global repression of
miRNA maturation process in cells and have identified
that the abrogation of miRNA processing pathway pro-
motes the cellular transformation and tumorigenesis
[91]. The inhibition of Dicer1 activity on its own has
also been associated with cancer development, invasion
and lymph node metastasis [91-94]. Therefore, speeding
up the miRNA processing globally or by replacement of
Dicer1 in cancer cells can alter their progression and in-
vasive potential. However, the effects of alterations in
miRNA biogenesis pathway have found to vary for differ-
ent tumour types [92,93] and therapeutic strategy will
vary dependent on the response for inhibition or acceler-
ation of miRNA processing.
Cancer stem cell directed miRNA therapy
Cancer stem cells or tumor-initiating cells have recently
gained enormous attention. According to this hypothesis
a subpopulation of cancer cells possesses unique charac-
teristics of self renewal and multipotent differentiation;
fundamental characteristics of embryonic and somatic
stem cells [95]. As cancer stem cells or tumor-initiating
cells are highly resistant to conventional chemotherapy
and radiotherapy [96,97] there is further need for stem
cell targeted therapy. Accumulating evidence indicates
that miRNAs play functional roles in normal and cancer
stem cell maintenance and differentiation. MiRNA ex-
pression signatures for differentiated cells are distinctly
different from embryonic and somatic stem cells [98,99].
However, miRNA expressions in cancer stem cells have
significant similarities with embryonic and somatic stem
cells. Monzo and colleagues studied the common miR-
NAs for CRC and embryonic tissue and suggested that
the miR-17-92 cluster and its target, E2F1, exhibit a
Figure 6 Figure illustrates the mechanisms of restoration of tumour suppressor miRNAs. The knockdown of oncogenic mRNAs can be
achieved by restoration of tumour suppressor miRNAs by a) Transcription activation of miRNA transcribing gene b) Transfection of tumour cells
with miRNA transcription gene linked to a virus construct e.g. adenovirus-associated vector (AAV) c) Introduction of synthetic precursor miRNAs in
tumour cells d) Synthetic miRNA mimics competing with mature miRNAs for RISC.
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ment and colonic carcinogenesis [43]. Further studies
dealing with miRNA biogenesis and stem cells; have sug-
gested that mutation of the key proteins in miRNA bio-
genesis pathway fail to maintain the self-renewal and
differentiation capacities [99-102]. Recent studies have
demonstrated the role of let-7 in self renewal, differenti-
ation and regulation of progenitor maintenance. Low ex-
pression of let-7 in cancer stem cells and restoration of
stem cell related miRNAs expression level in cancer cells
might prove pivotal in treating cancers by modulating
cancer stem cells.
Conclusions
In summary, there is strong evidence that miRNAs play
a significant role in CRC development and progression.
There is emerging evidence that miRNAs interact with
different cancer signalling pathways and control cellularhomeostasis. Changes in miRNAs expression levels
results in alteration of this homeostasis and significantly
contribute in cancer development and progression. Can-
cer specific miRNAs are detectable in body fluids and can
potentially be used as novel biomarkers for CRC detection
and prediction of cancer specific survival. MiRNAs influ-
ence oncogenic potential and therefore strategies to
manipulate oncogenic or tumour suppressor miRNAs
can successfully halt tumour progression. Further-
more, miRNA manipulation strategies can potentially
be used as an adjuvant to other forms of anticancer
therapies as miRNA manipulation can be used to sen-
sitise drug resistant tumours. Finally, stem cell direc-
ted miRNA based therapies can be used to control
stemness and latency of cancer stem cells in order to
prevent the recurrence of tumour. However, miRNA
based gene therapy is still in its infancy, but does
hold great potential to replace current anticancer
Table 4 Summary of studies involving the restoration of silenced miRNAs in CRC cell lines
miRNAs Cell Line Target Method Reported effects of miRNA manipulation References
let-7a-1 DLD-1 Ras let-7a-1 precursor Reduced cell viability, cell growth and
colony formation
Akao, et al, 2006 [27]
SW480 c-myc
miR-34a DLD-1 Sirt1 miR-34a mimic Reduced cell growth Akao, et al, 2011[75]
E2F3 Enhanced sensitivity to 5-FU
miR-34a Rko Axl pre-miR-34a Reduced migration & invasion Mudduluru, et al, 2011 [76]
miR-133b SW-620 HT-29 tyrosine kinase MET miR-133b precursor Reduces cell proliferation Increased apoptosis Hu, et al, 2010 [81]
miR-135a/b CLY CM-1 cytotoxicity miR-135a, Increased sensitivity to anticancer agent Li , et al, 2011[82]
HT-29 miR -135b mimics
miR-137 SW1116, Cdc42 miR-137 mimic Reduces cell proliferation , Cell cycle arrest Liu, et al, 2011[83]
Lovo, Colo320 Inhibition of invasion
miR-143 SW480, DNMT3A miR-143 precursor Reduces cell proliferation Ng, et al, 2009 [79]
228
miR-143 DLD-1 miR-143 precursor tumor-suppressive effect on xenografted
tumors of DLD-1 human CRC cells
Nakagawa, et al, 2010 [80]
miR-145 LS174T FLI1 miR-145 precursor Reduces cell proliferation and colony formation Zhang , et al, 2011 [84]
SW620 HCT116
miR145 HCT116 IRS-1 ds-oligos miR145 Reduces cell proliferation Shi , et al, 2007 [85]
KO
miR-185 SW1116 Lovo RhoA Cdc42 hsa-miR-185 mimic Cell cycle arrest & growth suppression Liu, et al, 2010 [86]
miR-192 RKO, LoVo,
DLD1, SW620
TYMS Pre-miR-192 Reduces cell proliferation Boni, et al, 2010 [87]
miR-195 HT29 and LoVo Bcl-2 miR-195 mimic Reduces cellular viability Increased apoptosis Liu, et al, 2010 [88]
Reduced colony formation
miR-196a SW480 HoxA7, HoxB8,
HoxC8 HoxD8
miR-196a mimics Reduced migration , invasion Schimanski, et al, 2009 [89]
Increased cellular adhesion
Increased sensitivity to platin derived
anticancer agents
miR-199a Rko Axl pre-miR-199a Reduced migration , invasion Mudduluru, et al, 2011[76]




TYMS pre-miR-215 Reduces cell proliferation Boni, et al, 2010 [87]
miR-491 DLD-1 Bcl-XL miR-491 precursor Reduces cell proliferation Nakano, et al, 2010 [90]
Increased apoptosis
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sue specific delivery system and strategies to avoid
side effects.
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